Our Focus
Fractyl targets root causes of obesity and type 2 diabetes, which are progressive metabolic diseases not addressed by current drug regimens.
fractyl.comCrawled Nov 18, 2026
Fractyl targets root causes of obesity and type 2 diabetes, which are progressive metabolic diseases not addressed by current drug regimens.
Obesity increases risks of metabolic syndrome, type 2 diabetes, high blood pressure, and heart disease.
Fractyl’s therapies focus on metabolic control organs like the duodenum and pancreas to address obesity and type 2 diabetes.
Fractyl’s research targets the duodenum and pancreas as key organs for metabolic disease treatment.
Rejuva is a preclinical gene therapy platform designed for one-time treatment of obesity and type 2 diabetes by enhancing pancreatic islet function.
Type 2 diabetes impairs blood sugar control, leading to chronic inflammation, cardiovascular disease, and other serious health issues.
Fractyl’s Erase Task Force advances research on gut-related metabolic disease, led by experts in the field.
Sabadell-Basallote et al., presented at ADA 2026
Media resources include a corporate deck, brochure, logos, and fact sheets for Fractyl’s REMAIN-1 study and Revita procedure.
Fractyl offers career opportunities in developing therapies for obesity and type 2 diabetes.
Ajay Royan created and runs Mithril, a growth fund that makes concentrated investments in transformative and durable technology companies around the world.
Kelly Barnes retired from PricewaterhouseCoopers (PwC) after 32 years, most recently as Global and US Health Industries Leader.
Len Rosberg leads manufacturing at Fractyl Health, with over 20 years of experience in supply chain and medical device manufacturing.
Management Team Board of Directors
Sarah Toomey serves as General Counsel and Corporate Secretary at Fractyl Health, bringing expertise in intellectual property, financing, and regulatory compliance.
Senator William W. Bradley represented New Jersey in the U.S. Senate from 1979 to 1997 and ran for the Democratic presidential nomination in 2000.
Fractyl provides machine-readable files of in-network negotiated rates and out-of-network allowed amounts under the Transparency in Coverage Rule.
Fractyl focuses on gut-based therapies to address obesity and type 2 diabetes, aiming for durable disease-modifying treatments.
Please sign up for ongoing news and information 3 Van de Graaff DriveSuite 200Burlington, MA 01803 For General Inquiries: (781) 902-8800info@fractyl.com For Investor Inquiries: Lara Smith WeberChief Financial Officer(617) 835-5912 Brian LuqueHead of Investor Relations and Corporate Development(951) 206-1200 IR@fractyl.com
Fractyl pursues therapies targeting root causes of obesity and type 2 diabetes to break the cycle of disease progression.
Fractyl’s patent portfolio protects its products, including the Revita System, under U.S. and international patents.